Optimizing decision making in hodgkin lymphoma

Susan K. Parsons, Joshua T. Cohen, Andrew M. Evens

Research output: Chapter in Book/Report/Conference proceedingChapter


Given the success of frontline treatments and the ability to salvage the majority of Hodgkin lymphoma (HL) patients after disease progression or recurrence, the short-term overall survival of HL is high. However, this survival comes at a cost to patients in the form of late effects, which can alter both the length and quality of survivorship. To reduce downstream late-effect risk while preserving excellent disease control, modifications have been made in frontline therapy, including changes in indications for radiation, reduction in radiation dose and field among those receiving treatment, risk stratification to determine need for either dose reduction or dose escalation to optimize outcomes, and incorporation of novel agents, initially in the salvage setting and more recently in frontline therapy. To guide patients and their families, alongside their providers, we describe the process of developing robust and nimble decision models to enhance and optimize the difficult decisions that affect acute and long-term outcomes.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
Number of pages9
StatePublished - Jan 1 2020

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


  • Decision models
  • Decision-making
  • Hodgkin lymphoma
  • Late effects
  • Simulation
  • Trade offs


Dive into the research topics of 'Optimizing decision making in hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this